{"nct_id":"NCT03924856","title":"Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2019-06-13","start_date_type":"ACTUAL","primary_completion_date":"2026-01-26","primary_completion_date_type":"ESTIMATED","completion_date":"2026-09-01","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}